A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology

American Heart Journal

Volumn 153, Issue 6, 2007, Pages 1037-1047

  Macchia, Alejandro ^a   Marchioli, Roberto ^a   Marfisi, RosaMaria ^a   Scarano, Marco ^a   Levantesi, Giacomo ^a   Tavazzi, Luigi ^b   Tognoni, Gianni ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE;

ARTICLE; CINAHL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DYSPNEA; EMBASE; EXERCISE; EXPERIMENTAL THERAPY; HUMAN; MEDICAL DOCUMENTATION; MEDLINE; META ANALYSIS; METHODOLOGY; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SURVIVAL; SYSTEMATIC REVIEW; WALKING;

EPOPROSTENOL; EXERCISE; EXERCISE TOLERANCE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ENDOTHELIN; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34249302372     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.02.037     Document Type: Article

References (44)

1. Gaine S.P., and Rubin L.J. Primary pulmonary hypertension. Lancet 352 (1998) 719-725
2. Runo J.R., and Loyd J.E. Primary pulmonary hypertension. Lancet 361 (2003) 1533-1544
3. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216-223
4. Sandoval J., Bauerle O., Palomar A., et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89 (1994) 1733-1744
5. Okada O., Tanabe N., Yasuda J., et al. Prediction of life expectancy in patients with primary pulmonary hypertension. A retrospective nationwide survey from 1980-1990. Intern Med 38 (1999) 12-16
6. Rajasekhar D., Balakrishnan K.G., Venkitachalam C.G., et al. Primary pulmonary hypertension: natural history and prognostic factors. Indian J Heart 46 (1994) 165-170
7. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 Suppl S (2004) 5S-12S
8. Farber H.W., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 (2004) 1655-1665
9. Moncada S., Gryglewski R., Bunting S., et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 (1976) 663-665
10. Gerber J.G., Voelkel N., Nies A.S., et al. Moderation of hypoxic vasoconstriction by infused arachidonic acid: role of PGI2. J Appl Physiol 49 (1980) 107-112
11. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
12. Hassoun P.M., Thappa V., Landman M.J., et al. Endothelin 1 mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med 199 (1992) 165-170
13. Stelzner T.J., O'Brien R.F., Yanagisawa M., et al. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 262 (1992) L614-L620
14. Benigni A., and Remuzzi G. Endothelin antagonists. Lancet 353 (1999) 133-138
15. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
16. Stewart D.J., Levy R.D., Cernacek P., et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
17. Rubens C., Ewert R., Halank M., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120 (2001) 1562-1569
18. Giaid A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 (1995) 214-221
19. McQuillan L.P., Leung G.K., Marsden P.A., et al. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am J Physiol 267 (1994) H1921-H1927
20. Petitti D.B. Meta-analysis, decision analysis, and cost-effectiveness analysis (1994), Oxford University Press, London, UK
21. Agresti A. Categorical data analysis (1990), John Wiley & Sons, Inc, NewYork
22. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9 (1987) 1-30
23. Higgins J.P.T., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
24. Tabachnick B., and Fidell L. Using multivariate statistics (1996), Harper Collins, New York (NY)
25. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med 112 (1990) 485-491
26. Barst R.J., Rubin L.J., Long W.A., et al., for The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-301
27. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 132 (2000) 425-434
28. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
29. Galie N., Humbert M., Vachiery J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
30. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
31. Barst R.J., McGoon M., McLaughlin V., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
32. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
33. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
34. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
35. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur J Respir 24 (2004) 353-359
36. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
37. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360 (2002) 895-900
38. Sastry B.K., Narasimhan C., Reddy N.K., et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004) 1149-1153
39. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
40. Wilkins M.R., Paul G.A., Strange J.W., et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study. Am J Respir Crit Care Med 171 (2005) 1292-1297
41. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
42. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
43. Anand I.S., Florea V.G., and Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 39 (2002) 1414-1421
44. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788